Anti-Infectives Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gilead Sciences, Inc.
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
August 3rd, 2009
Gilead Sciences, Inc. (Nasdaq:GILD) today highlighted results from a study known as DART (Development of Anti-Retroviral Treatment in Africa), which evaluated the need for routine laboratory monitoring in adults taking antiretroviral therapy in Africa. The DART trial was an open-label, randomized study comparing clinical and laboratory monitoring to clinical monitoring alone for efficacy and toxicity. In this study, 74 percent of patients were on a treatment regimen containing Viread® (tenofovir disoproxil fumarate). At baseline, more than 50 percent of patients had reduced renal function. The results indicated that Viread was well tolerated and that the incidence of renal adverse...
Source: Anti-Infectives Week (2009-08-03)
|
